Universal Beteiligungs und Servicegesellschaft mbH Decreases Position in Revvity Inc. (NYSE:RVTY)

Universal Beteiligungs und Servicegesellschaft mbH cut its stake in shares of Revvity Inc. (NYSE:RVTY - Free Report) by 4.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 139,551 shares of the company's stock after selling 6,429 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.12% of Revvity worth $14,764,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Optiver Holding B.V. bought a new position in shares of Revvity in the 4th quarter worth approximately $33,000. Quarry LP raised its position in shares of Revvity by 45.7% in the 4th quarter. Quarry LP now owns 303 shares of the company's stock worth $34,000 after acquiring an additional 95 shares in the last quarter. Vermillion Wealth Management Inc. bought a new position in shares of Revvity in the 4th quarter worth approximately $41,000. Continuum Advisory LLC raised its position in shares of Revvity by 39.3% in the 4th quarter. Continuum Advisory LLC now owns 471 shares of the company's stock worth $53,000 after acquiring an additional 133 shares in the last quarter. Finally, GeoWealth Management LLC bought a new position in shares of Revvity in the 4th quarter worth approximately $60,000. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Revvity Stock Down 9.9%

Shares of RVTY traded down $10.27 during midday trading on Monday, hitting $93.40. 1,839,911 shares of the company's stock traded hands, compared to its average volume of 1,149,658. Revvity Inc. has a 1 year low of $87.70 and a 1 year high of $129.50. The firm's fifty day moving average is $95.53 and its 200-day moving average is $103.26. The company has a current ratio of 3.58, a quick ratio of 2.99 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $11.01 billion, a price-to-earnings ratio of 39.75, a price-to-earnings-growth ratio of 2.61 and a beta of 0.98.

Revvity (NYSE:RVTY - Get Free Report) last released its earnings results on Monday, July 28th. The company reported $1.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.04. The firm had revenue of $720.28 million for the quarter, compared to the consensus estimate of $711.26 million. Revvity had a return on equity of 7.73% and a net margin of 10.35%. The firm's revenue was up 4.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.22 EPS. As a group, sell-side analysts anticipate that Revvity Inc. will post 4.94 earnings per share for the current year.

Revvity Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 17th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.30%. The ex-dividend date of this dividend is Friday, October 17th. Revvity's payout ratio is currently 11.91%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Wells Fargo & Company decreased their target price on Revvity from $130.00 to $102.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Barclays decreased their target price on Revvity from $140.00 to $110.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. Robert W. Baird reduced their price objective on Revvity from $127.00 to $125.00 and set an "outperform" rating for the company in a research report on Tuesday, April 29th. Evercore ISI reduced their price objective on Revvity from $116.00 to $115.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Finally, Raymond James Financial reaffirmed an "outperform" rating and set a $120.00 price objective (down previously from $145.00) on shares of Revvity in a research report on Tuesday, April 29th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $123.07.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.